Challenges
Datasets
Workspaces
Papers
Discussions
Leaderboard
Log inSign up
Challenges
Datasets
Workspaces
Papers
Discussions
Leaderboard
Blog
Job Board
Q3AS

© 2026 Aqora Quantum S.A.S.

TermsPrivacyLegal Notice

arXiv:2301.04114 · Nature Physics

Drug design on quantum computers

Raffaele Santagati, Alán Aspuru‐Guzik, Ryan Babbush, Matthias Degroote, Leticia González, Elica S. Kyoseva, Nikolaj Moll, Markus Oppel, Robert M. Parrish, Nicholas C. Rubin, Michael Streif, Christofer S. Tautermann, Horst Weiß, Nathan Wiebe, Clemens Utschig-Utschig

Published Mar 4, 2024• 133 citations
arXivHTMLPDF
DOI
10.1038/s41567-024-02411-5

Related papers

Insight into Quantum Computing and Deep Learning Approach for Drug Design

Deepika Paliwal, Siva Naga Koteswara Rao Gudhanti, Devdhar Yadav +1 more

Letters in Drug Design & Discovery•Apr 27, 2023•6 citations

Quantum Computing will Revolutionize Chemical Analysis, Drug Discovery and New Material Design

Doug Finke

Juniper Online Journal Material Science•Mar 5, 2020•0 citations

A Brief Review on Quantum Drug Design

Avishek Ray, Poulami Das, Siddhartha Bhattacharyya +3 more

Smart innovation, systems and technologies•Jan 1, 2024•1 citation

A brief review on quantum computing based drug design

Poulami Das, Avishek Ray, Siddhartha Bhattacharyya +5 more

Abstract Design and development of new drug molecules are essential for the survival of human society. New drugs are designed for therapeutic purposes to combat new diseases. Besides treating new diseases, new drug development is also needed to treat pre‐existing diseases more effectively and reduce the existing drugs' side effects. The design of drugs involves several steps, from the discovery of the drug molecule to its commercialization in the market. One of the most critical steps in drug design is to find the molecular interactions between the target (infected) molecule and the drug molecule. Several complex chemical equations need to be solved to determine the molecular interactions. In the late 20th Century, the advancement of computational technologies has made the solution of chemical equations relatively easier and faster. Moreover, the design of drug molecules involves multi‐criteria optimization. Classical computational methodologies have been used for drug design since the end of the 20th Century. However, nowadays, more advanced computational methodologies are inevitable in designing drugs for new diseases and drugs with fewer side effects. In this context, the quantum computing paradigm has proved beneficial in drug design due to its advanced computational capabilities. This paper presents a state‐of‐the‐art comprehensive review of the quantum computing‐based methodologies involved in drug design. A comparative study is made about the different quantum‐aided drug design methods, stating each methodology's merits and demerits. The review work presented in this manuscript will help new researchers assess the present state‐of‐the‐art concept of quantum‐based drug design. This article is categorized under: Technologies > Structure Discovery and Clustering Technologies > Computational Intelligence Application Areas > Health Care

Wiley Interdisciplinary Reviews Data Mining and Knowledge Discovery•Jul 16, 2024•8 citations

Quantum Computing in Drug Discovery

Nilesh Ingale Nilesh Ingale

INTERANTIONAL JOURNAL OF SCIENTIFIC RESEARCH IN ENGINEERING AND MANAGEMENT•Sep 1, 2026•0 citations

A hybrid quantum computing pipeline for real world drug discovery

Weitang Li, Zhi Yin, Xiaoran Li +10 more

Quantum computing, with its superior computational capabilities compared to classical approaches, holds the potential to revolutionize numerous scientific domains, including pharmaceuticals. However, the application of quantum computing for drug discovery has primarily been limited to proof-of-concept studies, which often fail to capture the intricacies of real-world drug development challenges. In this study, we diverge from conventional investigations by developing a hybrid quantum computing pipeline tailored to address genuine drug design problems. Our approach underscores the application of quantum computation in drug discovery and propels it towards more scalable system. We specifically construct our versatile quantum computing pipeline to address two critical tasks in drug discovery: the precise determination of Gibbs free energy profiles for prodrug activation involving covalent bond cleavage, and the accurate simulation of covalent bond interactions. This work serves as a pioneering effort in benchmarking quantum computing against veritable scenarios encountered in drug design, especially the covalent bonding issue present in both of the case studies, thereby transitioning from theoretical models to tangible applications. Our results demonstrate the potential of a quantum computing pipeline for integration into real world drug design workflows.

arXiv:2401.03759•Scientific Reports•Jul 23, 2024•69 citations
Abstract Design and development of new drug molecules are essential for the survival of human society. New drugs are designed for therapeutic purposes to combat new diseases. Besides treating new diseases, new drug development is also needed to treat pre‐existing diseases more effectively and reduce the existing drugs' side effects. The design of drugs involves several steps, from the discovery of the drug molecule to its commercialization in the market. One of the most critical steps in drug design is to find the molecular interactions between the target (infected) molecule and the drug molecule. Several complex chemical equations need to be solved to determine the molecular interactions. In the late 20th Century, the advancement of computational technologies has made the solution of chemical equations relatively easier and faster. Moreover, the design of drug molecules involves multi‐criteria optimization. Classical computational methodologies have been used for drug design since the end of the 20th Century. However, nowadays, more advanced computational methodologies are inevitable in designing drugs for new diseases and drugs with fewer side effects. In this context, the quantum computing paradigm has proved beneficial in drug design due to its advanced computational capabilities. This paper presents a state‐of‐the‐art comprehensive review of the quantum computing‐based methodologies involved in drug design. A comparative study is made about the different quantum‐aided drug design methods, stating each methodology's merits and demerits. The review work presented in this manuscript will help new researchers assess the present state‐of‐the‐art concept of quantum‐based drug design. This article is categorized under: Technologies > Structure Discovery and Clustering Technologies > Computational Intelligence Application Areas > Health Care
Quantum computing, with its superior computational capabilities compared to classical approaches, holds the potential to revolutionize numerous scientific domains, including pharmaceuticals. However, the application of quantum computing for drug discovery has primarily been limited to proof-of-concept studies, which often fail to capture the intricacies of real-world drug development challenges. In this study, we diverge from conventional investigations by developing a hybrid quantum computing pipeline tailored to address genuine drug design problems. Our approach underscores the application of quantum computation in drug discovery and propels it towards more scalable system. We specifically construct our versatile quantum computing pipeline to address two critical tasks in drug discovery: the precise determination of Gibbs free energy profiles for prodrug activation involving covalent bond cleavage, and the accurate simulation of covalent bond interactions. This work serves as a pioneering effort in benchmarking quantum computing against veritable scenarios encountered in drug design, especially the covalent bonding issue present in both of the case studies, thereby transitioning from theoretical models to tangible applications. Our results demonstrate the potential of a quantum computing pipeline for integration into real world drug design workflows.